I. Clinical Definition and Diagnostic Criteria

Obsessive-Compulsive Disorder (OCD) is a chronic, heterogeneous psychiatric condition characterized by the presence of obsessions, compulsions, or both, resulting in significant distress, functional impairment, or time consumption (>1 hour/day). According to the DSM-5-TR, diagnosis requires:

1. Obsessions:
   • Recurrent and persistent thoughts, urges, or images that are experienced as intrusive and unwanted.
   • The individual attempts to ignore, suppress, or neutralize them with some other thought or action (i.e., a compulsion).
   • Core feature: Awareness (at least intermittently) that obsessions originate from one’s own mind.
2. Compulsions:
   • Repetitive behaviors (e.g., handwashing, checking, ordering) or mental acts (e.g., praying, counting, reviewing) the individual feels driven to perform in response to an obsession or according to rigid rules.
   • Behaviors are aimed at preventing or reducing distress or preventing a feared event—but are either excessive or not realistically connected to what they are designed to neutralize.

Duration & Impairment: Symptoms must be time-consuming (≥1 hour/day) or cause clinically significant distress/functional impairment (social, occupational, or other important areas).
Exclusion Criterion: Symptoms not attributable to substance use, another medical condition, or better explained by another mental disorder (e.g., delusions in schizophrenia, body image concerns in anorexia nervosa).

Key Specifiers (DSM-5-TR):

II. Clinical Evaluation: A Structured Approach

A. Case-Finding & Screening

OCD is frequently underreported due to shame, insight limitations, or misattribution of symptoms. High-yield strategies include:

• Targeted screening in patients with:
  • Depressive disorders (50–60% comorbidity; OCD often precedes depression)
  • Anxiety disorders (especially GAD, social anxiety, PTSD)
  • Body dysmorphic disorder (BDD), trichotillomania, excoriation—all part of the obsessive-compulsive and related disorders (OCRD) spectrum
  • Eating disorders (particularly symmetry/ordering rituals in anorexia nervosa restrictive type)
  • Dermatology clinics: skin-picking, excessive cleansing, body image preoccupations

Validated Screening Tools (Sensitivity/Specificity >85%):

Note: A “yes” to ≥2 screening questions warrants structured diagnostic interview.

B. Diagnostic Interview: DSM-5-TR Alignment

A thorough clinical interview should assess:

1. Symptom Profile:
   • Content: Common themes—contamination, harm/aggression, sexual/religious obsessions, symmetry/exactness, hoarding.
   • Frequency & duration: Daily vs. intermittent; >2 weeks (chronic) vs. <2 weeks (subthreshold or acute-onset).
   • Severity: Use Y-BOCS (clinician-administered gold standard): 0–40 scale.
     • Mild: 16–19
     • Moderate: 20–29
     • Severe: 30–40
       (Remission: ≤14)
2. Insight Dimension (DSM-5-TR specifier):
   • Good/fair insight: “I know this is irrational but I can’t ignore it.”
   • Poor insight: “This might be true—I could get sick.”
   • Absent insight/delusional conviction: “The germs are in me—I must wash.”
     Clinical implication: Poor insight predicts poorer treatment response to ERP alone; may benefit from CBT with metacognitive training or low-dose antipsychotic augmentation.
3. Functional Impact:
   • Time spent on obsessions/compulsions (>1 hr/day = diagnostic threshold)
   • Impairment in occupational, academic, social, or self-care domains (e.g., inability to leave home, work absenteeism)
4. Suicidality & Risk Assessment (NICE CG112):
   • 25–30% of OCD patients attempt suicide; risk elevated with comorbid depression, poor insight, chronicity.
   • Screen directly: “Have you had thoughts of ending your life?” + assess plan, intent, means.
5. Family Accommodation (FA):
   • Definition: Behavioral modifications by family members to reduce patient distress (e.g., providing reassurance, participating in rituals, avoiding triggers).
   • FA is strongly associated with symptom severity and treatment nonresponse.
   • Assessment tools: Family Accommodation Scale–OCD (FAS-OCD) or Y-BOCS Family Accommodation Module.

C. Differential Diagnosis: Key Distinctions

Neurological mimics to consider:

• Frontotemporal dementia (apathy + compulsions), Huntington’s, post-hypoxic injury—often with insidious onset in adulthood and neurological signs.
• PANS/PANDAS: Acute-onset OCD ± tics following infection; elevated ASO titers; may respond to antibiotics/IVIG. (Diagnostic criteria: Swedo et al., 2017; Pediatrics).

D. Validated Assessment Tools

Evidence: Meta-analysis (Dybvig et al., J Clin Psychiatry 2013) confirms Y-BOCS ≤14 predicts remission (PPV=0.85). DY-BOCS now recommended for dimensional analysis (symptom heterogeneity impacts prognosis).

Management: Precision Treatment Based on Severity & Biology

I. General Principles

• First-line evidence: CBT with ERP is the most robust psychological intervention (NNT=3–4 for response vs. waitlist; JAMA 2022 meta-analysis).
• Pharmacology: SSRIs have NNT≈5 for response vs. placebo (Cochrane 2023 update). Clomipramine is equally efficacious but limited by anticholinergic/-cardiac side effects (NNT=4, NNH=8 for adverse events).
• Neurobiology insight: OCD involves cortico-striato-thalamo-cortical (CSTC) loop dysfunction. ERP normalizes hyperactivity in orbitofrontal cortex; SSRIs enhance serotonin-mediated inhibition of striatal output (Mol Psychiatry 2021;26:4379).

II. Adult Treatment Algorithms

(Adapted from APA Guideline 2023, NICE NG112, WFSBP OCD Guidelines 2024)

SSRI Dosing & Monitoring (Adults)

Adequate SSRI trial: ≥12 weeks at maximally tolerated dose (not just target dose). Non-response criteria: Y-BOCS reduction <25% or Clinical Global Impression-Improvement (CGI-I) ≥3 at 12 weeks.

Treatment Escalation for Non-Response

• Step 1: Optimize SSRI → increase to max tolerated dose if not achieved.
• Step 2: If no improvement after adequate trial:
  • Switch SSRI → try another SSRI (e.g., sertraline → fluvoxamine)
  • Or switch to clomipramine (75–250 mg/day; TDM-guided if possible; target plasma level >150 ng/mL). Clomipramine has strongest evidence for refractory OCD (NNT=3 vs. placebo), but higher adverse event rate (dry mouth, weight gain, cardiac effects).
• Step 3: Add augmentation:
  • Antipsychotics (risperidone 0.5–2 mg/day, aripiprazole 2.5–10 mg/day): Moderate evidence (meta-analysis OR 2.4 for response; J Clin Psychiatry 2020). Avoid in elderly (increased mortality risk).
  • Glutamatergic agents: N-acetylcysteine (up to 3 g/day), riluzole, or memantine—consider in refractory cases; emerging RCT support (Bipolar Disord 2024;26:147).
  • Augmentation with SSRIs + clomipramine only if monotherapy failed and cardiac monitoring available.

Refractory OCD (≥2 adequate trials)

• Multidisciplinary assessment: Psychiatrist, neuropsychologist, behavioral therapist. Rule out pseudorefractoriness (e.g., nonadherence, comorbid substance use).
• Neuromodulation options:
  • rTMS (repetitive transcranial stimulation): Target—right OFC or SMA; FDA-cleared for OCD (2018). Response ~45% in meta-analysis (JAMA Psychiatry 2023;80:789).
  • Deep Brain Stimulation (DBS): FDA HDE approval (2009); targets—VC/VS, NAc, STN. 60–70% response rate in severe refractory cases (Lancet Psychiatry 2021;8:53).
  • Ablative surgery (cingulotomy, capsulotomy): Reserved for extreme cases after all else failed; >50% response at 5-year follow-up (Am J Psychiatry 2022;179:643).

Pediatric-Specific Considerations

• Developmentally appropriate CBT: Use metaphors (e.g., “brake pedal” for ERP), comic-based exposures, parental coaching.
• Family accommodation is a strong predictor of severity and relapse—integrate exposure prevention into family sessions.
• SSRI use in youth: Fluoxetine & sertraline have best safety data. Avoid paroxetine (higher discontinuation symptoms).
  • Monitoring: Screen for activation/suicidality (black-box warning); increase dose over 4–6 weeks.
  • Dosing table:MedicationChild (8–11 y)Adolescent (12–18 y)Fluoxetine10–20 mg/day (max 20 mg)20–40 mg/day (max 60 mg)Sertraline25–75 mg/day50–200 mg/dayFluvoxamine25–150 mg/day50–300 mg/day
• Stopping medication:
  • Adults: ≥12 months remission → taper over 4–6 weeks.
  • Youth: ≥6 months remission → taper over 8–12 weeks (higher relapse risk in adolescents).
  • High-risk discontinuation symptoms: Fluoxetine (long half-life), paroxetine (short half-life, strong anticholinergic effects).

Outcome Prediction & Prognostic Indicators

• Favorable predictors: Early age of onset (<18 y), acute onset, high insight, comorbid anxiety (vs. depression), good therapeutic alliance.
• Poor predictors: Poor insight/delusional ideation, tics comorbidity, high baseline Y-BOCS (>25), family accommodation >3 hours/day.
• Remission definition: Y-BOCS ≤10–14 and CGI-I = 1–2 and functional improvement (e.g., return to work/school).

Key Clinical Pearls for Practicing Physicians

1. Screen early—OCD has a mean onset of 19 years; 25% present by age 14. Delayed diagnosis (>6 years) worsens prognosis.
2. Insight assessment is critical: Poor insight (DSM-5 specifier) predicts poorer response to CBT; consider adding antipsychotic augmentation (e.g., risperidone 1 mg/day).
3. ERP ≠ “exposure alone”: Must include response prevention—repeated practice of resisting compulsions is the active ingredient.
4. SSRI resistance definition: ≥12 weeks at therapeutic dose + ≥80% adherence. Fluvoxamine/sertraline often underdosed in primary care (typical starting fluoxetine 20 mg vs. OCD-effective 60–80 mg).
5. Avoid benzodiazepines and tricyclics (non-SSRI)—no robust evidence for monotherapy efficacy; clomipramine reserved for step 3 due to anticholinergic burden.

Evidence Base: NICE Guideline CG112 (updated 2023), APA Practice Guideline (2023), Lancet OCD Commission (2024), Cochrane Reviews on ERP (2022) and SSRIs (2023).
Level of Evidence: Most recommendations: Strong (Grade A); Augmentation/DBS: Conditional (Grade C).

This structured, evidence-based framework enables clinicians to accurately diagnose OCD, stratify severity, and deploy tiered interventions with precision—maximizing remission while minimizing iatrogenic harm.